文献速递衰弱、肌少症与跌倒老年慢病共病管理

地舒单抗治疗长期护理机构老年骨质疏松:一项随机试验

Denosumab for osteoporosis in older adults in long-term care: A randomized trial.
PubMed 文献 · J Am Geriatr Soc · 2024-11-10

在长期护理机构中开展2年双盲安慰剂对照随机试验,纳入201例≥65岁骨质疏松患者,每6个月皮下注射地舒单抗60 mg或安慰剂。24个月时女性和男性脊柱及全髋骨密度增幅均显著优于安慰剂,安全性指标无显著差异。

要点

  • 地舒单抗每6个月60 mg皮下注射可显著提高长期护理机构老年男女脊柱和全髋骨密度。
  • 该人群多病共存、活动障碍和认知障碍者未被排除,安全性指标与安慰剂无显著差异。
  • 24个月时女性和男性脊柱及全髋骨密度增幅均显著优于安慰剂。

核心结论

  • 地舒单抗对长期护理机构中多病共存的老年骨质疏松男女是安全有效的骨密度改善治疗。

研究设计与样本

  • 2年双盲安慰剂对照随机临床试验,纳入201例≥65岁居住在长期护理社区的骨质疏松男女。
  • 干预为地舒单抗60 mg皮下注射每6个月一次或安慰剂,主要结局为24个月髋部和脊柱骨密度改善。

主要发现

  • 女性地舒单抗组24个月脊柱骨密度增幅7.41±0.93% vs 安慰剂2.15±0.56%(p=0.014)。
  • 女性地舒单抗组24个月全髋骨密度增幅4.62±0.62% vs 安慰剂-0.19±0.79%(p=0.007)。
  • 男性地舒单抗组24个月脊柱骨密度增幅7.91±0.96% vs 安慰剂1.12±1.13%(p=0.002)。
  • 男性地舒单抗组24个月全髋骨密度增幅3.74±0.55% vs 安慰剂0.48±0.74%(p=0.018)。
  • 安全性指标无显著差异。

临床怎么用

  • 对长期护理机构中多病共存、活动障碍或认知障碍的老年骨质疏松患者,可考虑每6个月皮下注射地舒单抗60 mg以改善骨密度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In long-term care (LTC), the incidence of hip or vertebral fractures are eight times that in the community. Despite the wide availability of osteoporosis therapy, LTC residents are omitted from pivotal trials and not treated. Denosumab is a relatively new, monoclonal antibody therapy for osteoporosis treatment. Via a randomized trial, we sought to determine the safety and efficacy of denosumab in LTC residents. METHODS: We conducted a 2-year, double-blind, placebo-controlled, randomized clinical trial in 201 osteoporotic men and women aged ≥ 65 years, living in LTC communities. Participants with multimorbidity, dysmobility, and cognitive impairment were not excluded. The intervention was denosumab 60 mg subcutaneous every 6 months or placebo. Our primary outcome measures were hip and spine bone mineral density (BMD) improvement at 24 months. Secondary outcomes included BMD at other skeletal sites, function, and safety. RESULTS: We included 123 women and 78 men with a mean ± standard error age of 81.5 ± 0.6. Overall, 83% and 71% completed 12 and 24 months, respectively. Compared with placebo, the women receiving denosumab had a greater 24-month percent increase in spine (7.41 ± 0.93 vs. 2.15 + 0.56; p = 0.014), and total hip BMD (4.62 ± 0.62 vs. -0.19 ± 0.79; p = 0.007); and men in spine (7.91 ± 0.96 vs. 1.12 ± 1.13; p = 0.002) and total hip (3.74 ± 0.55 vs. 0.48 ± 0.74; p = 0.018). There were no significant differences in safety metrics. CONCLUSIONS: Denosumab was a safe and effective therapy for improving BMD in osteoporotic older men and women with multiple comorbidities in LTC.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Greenspan SL, Perera S, Haeri NS, et al. Denosumab for osteoporosis in older adults in long-term care: A randomized trial. J Am Geriatr Soc. 2024. PMID: 39523676. doi:10.1111/jgs.19260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。